To investigate the endogenous signaling pathways associated with high proliferation potential of breast cancer cells. Methods: Breast cancer cell lines LM-MCF-7 and MCF-7 with high and low proliferation capability were used. The promoter activity of fatty acid synthase (FASN) was examined using luciferase reporter gene assay. The expression level of FASN mRNA was measured using RT-PCR and real time PCR, respectively. The level of leukotriene B4 (LTB4) was determined with ELISA. The expression levels of 5-lipoxygenase (5-LOX) was analyzed using RT-PCR and Western blot, respectively. 5-Bromo-20-deoxyuridine (BrdU) incorporation assay was used to study the proliferation of LM-MCF-7 and MCF-7 cells. 
Introduction
Monod and Jacob reported that the feedback loops were present in eukaryotic signal transduction system in 1961 [1] . In the network of signaling transduction, the positive feedback loop regulation plays important roles in determining the progressive nature of malignant cancer cells including cell proliferation [2] [3] [4] [5] . Extracellular signal-regulated kinase 1/2 (ERK1/2), a major cellular proliferation signaling pathway, is involved in many positive feedback loops. Previously, we reported a positive feedback between the phosphorylated ERK1/2 (p-ERK1/2) and cyclooxygenases (COX)/lipoxygenases (LOX) [6] . Kim et al [7] discovered a positive feedback loop between Wnt and ERK pathways. It has also been reported that there is a regulatory loop between fatty acid synthase (FASN) and ERK pathway dependent on the HER1/HER2 [8] . Cheng et al [9] identified a positive feedback loop in which Ras signaling promoted CD44v6 splicing, and CD44v6 then sustained late Ras signaling. Moreover, ERK occurs crosstalk with other pathways, including activated stress activated protein kinase (SAPK)-p38 [10] , phosphatidylinositol 3-kinase (PI3K) [11] , Wnt [12] and myosin light-chain kinase (MLCK) [13] . Thus, p-ERK1/2 may serve as a key hub in the network.
FASN is a 250−270 kDa multifunctional, homodimeric enzyme responsible for energy storage by converting excess carbohydrate to fatty acids that are then sterified to store triacylglycerols [14] . Under normal physiological conditions, npg expression of FASN is tightly regulated in breast tissues, whereas deregulation of FASN occurs in cancer cells contributing to exacerbated lipogenesis required for highly proliferating cancer cell population [15] . The pharmacological and RNAi mediated inhibition of FASN leads to growth inhibition and cell apoptosis in several experimental models, suggesting that FASN may be a promising therapeutic target for cancer therapy [16] . Therefore, we are interested in the intracellular growth signaling pathways that are associated with FASN in breast cancer cells.
The contribution of arachidonic acid metabolites to cancer progression is becoming the focus of intense research, with the involvement of both COX and LOX pathways [17] . The LOX pathway has different isoenzymes, including 5-LOX, which converts arachidonic acid to hydroxyeicosatetraenoic acids or leukotrienes [18] . 5-LOX is often overexpressed in multiple tumor types and is involved in proliferation, survival, and apoptosis of cancer cells [19] . Leukotriene B4 (LTB4), the final metabolite in the 5-LOX pathway, is able to enhance proliferation, increase survival and suppress the apoptosis of human cells. Blockade of the LTB4-signaling pathway induced apoptosis via the inhibition of ERK1/2 activation in colon cancer cells [20] . However, the mechanisms that 5-LOX/LTB4 promotes breast cancer cell growth remain unclear.
Previously, our laboratory established a metastatic subclone from the MCF-7 breast cancer cell line, called LM-MCF-7, which was derived from a lung metastasis of a severe combined immunodeficient (SCID) mouse [21] . In vivo and in vitro experiments showed that LM-MCF-7 had high malignant phenotype in cell proliferation and migration [22] . The two cell lines, having the similar genetic background, provide excellent parallel models for investigating the molecular mechanisms underlying the sustained proliferation of breast cancer cells.
In the present study, we investigate the signal transduction pathway that maintains the growth of breast cancer cells using the parallel MCF-7/LM-MCF-7 breast cancer cell lines. We report a novel positive cascade loop in the network. Our data show that p-ERK1/2 is one of key hubs in the network. This finding provides new insight into the mechanisms of network regulation in breast cancer cells.
Materials and methods
Cell culture MCF-7 and LM-MCF-7 cells were cultured in RPMI-1640 (Gibco, USA) medium supplemented with 10% fetal calf serum (Gibco, USA), 100 U/mL penicillin, 100 mg/mL streptomycin and 1% glutamine. Cultures were incubated at 37 °C in a humidified atmosphere with 5% CO 2 .
Reagents MK-886 (an inhibitor of 5-LOX), NDGA (an inhibitor of LOX), indomethacin (Indo, an inhibitor of COX), PD98059 (a p42/44 MAPK inhibitor), SKF525A (a CYP450 inhibitor) and LTB4 were purchased from Sigma-Aldrich (USA). Pertussis toxin (PTX, an inhibitor of a Gi/o protein) was purchased from List Biological Laboratories Inc (USA). Cerulenin (an inhibitor of FASN) was purchased from Fermentek Ltd (Israel). The enzyme immunoassay kit for measurement of LTB4 was purchased from Adlitteram Diagnostic Laboratories (USA).
Small interfering RNA and plasmids transfection
The reporter construct, pFASN-WT-Luc, containing the promoter of FASN was kindly provided by Dr Qiang LIU (University of Saskatchewan, Canada). The small siRNAs (siRNAs) targeting human 5-LOX mRNA (NM_000698, 315 to 335) and human FASN mRNA (NM_004104.4, 1210 to 1231) and control siRNA were designed and synthesized by RiboBio (Guangzhou, China). The transfection with RNAi reagents and different dose of plasmids were performed using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's protocol, respectively.
Treatments of tumor cells
Cells were cultured in 24-well plates for 24 h, and then were recultured in serum-free medium for 12 h. In brief, LM-MCF-7 cells were treated with PTX (30 ng/mL or 50 ng/mL), Indo RNA isolation, RT-PCR and quantitative real-time PCR Total RNA isolation, RT-PCR and quantitative real-time PCR were performed as previously described [23] . Briefly, total RNA of cells was isolated using TRIzol reagent (Invitrogen, USA) according to the manufacturer's instructions. First-strand cDNA was synthesized with PrimeScript reverse transcriptase (TaKaRa Bio, China) and oligo (dT). After reverse transcription reaction, PCR and real-time PCR were performed by an ABI PRISM 7000 sequence detection system according to the manufacturer's instructions using double stranded DNA specific flurophore SYBR Green (Promega, USA). We included specific primers for FASN (forward primer, 5′-GGT CTT GAG AGA TGG CTT GC-3′ and reverse primer, 5′-AAT TGG CAA AGC CGT AGT TG-3′), 5-LOX (forward primer, 5′-CCC GGG GCA TGG AGA GCA-3′ and reverse primer, 5′-GCG GTC GGG CAG CGT GTC-3′). As a control, GAPDH was amplified with specific primers (forward primer, 5′-CAT CAC CAT CTT CCA GGA GCG-3′ and reverse primer, 5′-TGA CCT TGC CCA CAG CCT TG-3′). The conditions of PCR were as follows: 94 °C for 10 min, followed by 35 cycles of amplifications There is no nonspecific amplification determined by dissolved curves. There are three samples in each group. The real-time PCR results were reported as the fold induction of relative light units for the treatment over vehicle after normalization to GAPDH expression.
Luciferase reporter gene assay Treated MCF-7 and LM-MCF-7 cells grown in 24-well plates were cotransfected with 0.3 μg of a plasmid encoding firefly luciferase under the control of wild-type FASN promoter, and 0.05 μg of pRL-SV40 encoding Renilla luciferase (rLuc) (Promega, USA). Reporter luciferase assay was performed 48 h after transfection with Dual Luciferase Assay reagents (Promega, USA) using a TD 20/20 luminometer (Turner Designs). The luciferase readings of each sample were normalized against the rLuc levels. All of the data shown in this study were obtained from three independent experiments.
Western blot analysis Cells were washed with cold phosphate-buffered saline (PBS) for 3 times and lysed in RIPA cell lysis buffer (10 mmol/L HEPES pH 7.4, 0.15 mol/L NaCl, 1 mmol/L MgCl 2 , 1 mmol/L CaCl 2 , 1 mmol/L dithiothreitol, 0.1% sodium dodecylsulfate, 0.1% NP-40, and 20 μg/mL leupeptin). Protein concentrations were estimated using Bradford reagent (Bio-Rad, USA). Equal amount of total protein was loaded for immunoblotting. Following SDS-PAGE, resolved proteins were electrotransfered on PVDF membrane (Millipore, USA). The membrane was blocked overnight in TBS containing 0.1% Tween-20 (TBST) and 5% skim milk. The membrane was then probed with primary antibody in TBST for 2 h at room temperature or overnight at 4 °C , followed by three 15 min TBST washes at room temperature. Incubation with the secondary antibody was done for 1 h and three 10 min TBST washes were given prior to chemiluminiscence detection using ECL substrate (Amersham Biosciences, UK). The primary antibodies for Western blot followed a dilution below mouse anti-p-ERK1/2 monoclonal antibody (1:1000 dilution, Cell Signaling Technology, Danvers, MA, USA), rabbit anti-5-LOX monoclonal antibody (1:500 dilution, Santa Cruz Biotechnology), mouse anti-human β-actin monoclonal antibody (1:20 000 dilution, Sigma). The data were analyzed by applying Glyco Band-Scan software. All of the data shown in this study were obtained from three independent experiments.
Enzyme-linked immunosorbent assay (ELISA)
The amount of LTB4, a metabolite of 5-LOX, was determined by ELISA assay according to the instructions provided by the manufacturer. The concentration of LTB4 was normalized to total protein. The concentrations of LTB4 in these extracts were determined using a protein assay method (Bio-Rad).
BrdU incorporation assay
The detailed 5-Bromo-20-deoxyuridine (BrdU) incorporation assay procedure was described as previously [13] . In brief, LM-MCF-7 and MCF-7 cells were seeded in 6-well culture plate and were grown overnight prior to treatment. LM-MCF-7 cells were treated with 2.5, 5, and 10 μmol/L cerulenin for 8 h, or with 10 and 20 μmol/L MK-886 for 8 h, respectively. MCF-7 cells were treated with 1 and 10 nmol/L LTB4 for 8 h. All groups (n=3, in every group) were incubated with fresh medium containing 10 μmol/L BrdU (Sigma) for 4 h prior to immunofluorescence staining with mouse anti-BrdU antibody. The cells were fixed for 15 min with 4% paraformaldehyde in PBS. After 1 h incubation with PBS containing 2 mol/L HCl to denature DNA, cover slips were washed 3 times with 0.5% bovine serum albumin (BSA) and 0.5% Tween 20 in PBS, and incubated overnight (4 °C) with a mouse anti-BrdU antibody (NeoMarkers, Fremont, CA, USA) at 1:300 dilution. Reactions were developed using fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Dako, Glostrup, Denmark) at 1:100 dilution for BrdU staining. The BrdU labeling index was assessed by point counting through a Nikon TE200 inverted microscope (Nikon, Tokyo, Japan) using a 40×objective lens. About 700-800 nuclei were counted in 6-8 representative fields. The labeling index was expressed as the number of positively labeled nuclei/total number of nuclei. Propidium iodine (PI) (Sigma) (50 μg/mL) was used to stain nuclei as the control to all cells in each group. 
Statistical analysis
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Acta Pharmacologica Sinica npg p-ERK1/2 activates 5-LOX Our previous finding showed that PD98059 treatment led to a decrease of 5-LOX expression in breast cancer cells [6] . Here, we confirmed the results in the two cell lines as determined by RT-PCR and Western blot analysis, respectively (data not shown).
5-LOX/LTB4 activates FASN
Next, we investigated whether 5-LOX was involved in the upregulation of FASN. We treated LM-MCF-7 cells with increasing concentration of MK-886 (a specific 5-LOX inhibitor) for 6 h. Our finding showed that MK-886 was able to decrease the expression of FASN in a dose-dependent manner in LM-MCF-7 cells by luciferase reporter gene assays, RT-PCR and real-time PCR, respectively (Figure 2A-2B, P<0.05; P<0 .01 vs LM-MCF-7 cells, Student's t test). In addition, we found that siRNA targeting the mRNA of 5-LOX could significantly . 5-HETE, one of 5-LOX important products, has direct proliferating activity on a subset of cancers [24] . To demonstrate whether 5-HETE contributes to the upregulation of FASN, we examined the effect of 5-HETE on FASN promoter activity. Our data showed that the treatment with 5-HETE in MCF-7 cells failed to activate the promoter activity of FASN (data not shown). Thus, it suggests that 5-LOX/ LTB4, but not 5-HETE, is responsible for the upregulation of FASN.
LTB4/FASN activates the p-ERK1/2/5-LOX in a positive feedback manner Given several studies revealed that the effects of LTB4 were mediated through MEK/ERK pathway [25] [26] [27] , we speculated whether LTB4 could activate p-ERK1/2/5-LOX in a positive feedback manner in breast cancer MCF-7 cells. Interestingly, Western blot analysis showed that administration of exogenous LTB4 was able to increase the expression levels of p-ERK1/2 and 5-LOX in a dose-dependent manner ( Figure  3A ). In addition, we also investigated whether FASN could activate p-ERK1/2/5-LOX/LTB4 signaling in a positive 
Discussion
Previously, we reported that breast cancer cells grew faster in a positive feedback manner involving activated ERK and COX/LOX [6] . However, the endogenous signaling pathways associated with high proliferation potential of breast cancer cells remain unclear. Indeed, we are interested in the network regulation involving positive feedback loop manner in sustaining tumor growth. In this study, we focused on the investigation of positive feedback loop.
FASN is a complex multifunctional enzyme that plays a central role in endogenous lipogenesis in mammals [28, 29] . It has been reported that the overexpression of FASN together with a high proliferative index of breast cancer cells are associated with a nine-fold increased risk of patient mortality [30] . Accordingly, we examined the level of FASN by comparing breast cancer cell lines with different proliferative capability. Our data showed that the level of FASN promoter activity was positively correlated with the high proliferative ability Figure 1A ). Thus, we need to answer the upstream activators of FASN in breast cancer cells. Several studies have demonstrated the involvement of ERK1/2 pathways in regulating FASN expression in cancer cells [31, 32] . It has been reported that LOX or its metabolites are able to stimulate tumor cell proliferation [33] . In agreement, we identified that p-ERK1/2 and LOX were upstream regulators of FASN ( Figure 1B-1D) .
Several studies have reported that 5-LOX is able to enhance cell proliferation and increase cell survival [19, 34] . A recent study found that the expression levels of FASN and 5-LOX played important roles in mediating breast cancer formation [35] . Our previous observation showed that ERK1/2 activation increased the expression of 5-LOX in breast cancer cells [6] . In this text, we confirmed the data (data not shown). Activation of ERK1/2 and overexpression of 5-LOX are frequently observed in various human tumors [36, 37] . Thus, we conclude that p-ERK1/2 activates 5-LOX in breast cancer cells. The final product of the 5-LOX pathway is LTB4, which is able to enhance tumor growth, including enhancing proliferation and suppressing apoptosis in human cancer cells [38] . Therefore, we present a hypothesis that a link between 5-LOX metabolism and FASN may contribute to sustaining high proliferation rate of breast cancer cells. Interestingly, we found that the blockade of 5-LOX with MK-886 or siRNAs was able to significantly decrease the expression level of FASN in LM-MCF-7 cells (Figure 2A-2C) . Then, we examined the amount of LTB4 in the conditioned media from breast cancer cells. Our data showed that the level of LTB4 was higher in the cellular extracts from LM-MCF-7 cells relative to MCF-7 cells, which was abolished by the treatment with MK-886 ( Figure 2D) . Interestingly, the administration of exogenous LTB4 was able to enhance the expression of FASN (Figure 2E-2F) . Moreover, we examined the effect of 5-HETE, another product of 5-LOX, on FASN. Our data showed that 5-HETE failed to activate the promoter activity of FASN in MCF-7 cells. Thus, we conclude that 5-LOX/LTB4, but not 5-HETE, is responsible for the upregulation of FASN.
Currently, feedback mechanisms have been implicated in the carcinogenesis. Our previous study showed that 5-LOX plays an important role in the activation of ERK1/2 [39] . Studies by Tong et al [25] have shown that the growth stimulatory effect of LTB4 is mediated at least through MEK/ERK pathway in human pancreatic cancer cells. Consistently, we here report a novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN that is responsible for the sustained high proliferation of breast cancer cells (Figures 3, 4) .
Taken together, we conclude that a novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains a high proliferative potential of breast cancer cells, in which p-ERK1/2 is one of key hubs in the network. Our finding provides a new insight into the mechanism involving the high growth ability of breast cancer cells.
